Display options
Cite
Fasler-Kan E, Aliu N, Haecker FM, et al. Chromosomal Heterogeneity of the G-401 Rhabdoid Tumor Cell Line: Unusual Partial 7p Trisomy. Front Med (Lausanne). 2019;6:187doi: 10.3389/fmed.2019.00187.
Fasler-Kan, E., Aliu, N., Haecker, F. M., Maltsev, N., Ruggiero, S., Cholewa, D., Bartenstein, A., Milošević, M., & Berger, S. M. (2019). Chromosomal Heterogeneity of the G-401 Rhabdoid Tumor Cell Line: Unusual Partial 7p Trisomy. Frontiers in medicine, 6187. https://doi.org/10.3389/fmed.2019.00187
Fasler-Kan, Elizaveta, et al. "Chromosomal Heterogeneity of the G-401 Rhabdoid Tumor Cell Line: Unusual Partial 7p Trisomy." Frontiers in medicine vol. 6 (2019): 187. doi: https://doi.org/10.3389/fmed.2019.00187
Fasler-Kan E, Aliu N, Haecker FM, Maltsev N, Ruggiero S, Cholewa D, Bartenstein A, Milošević M, Berger SM. Chromosomal Heterogeneity of the G-401 Rhabdoid Tumor Cell Line: Unusual Partial 7p Trisomy. Front Med (Lausanne). 2019 Aug 30;6:187. doi: 10.3389/fmed.2019.00187. eCollection 2019. PMID: 31544104; PMCID: PMC6729120.
Copy Download .nbib Format: NLM
Share it on

Front Med (Lausanne). 2019 Aug 30;6:187. doi: 10.3389/fmed.2019.00187. eCollection 2019.

Chromosomal Heterogeneity of the G-401 Rhabdoid Tumor Cell Line: Unusual Partial 7p Trisomy.

Frontiers in medicine

Elizaveta Fasler-Kan, Nijas Aliu, Frank-Martin Haecker, Natalia Maltsev, Sabrina Ruggiero, Dietmar Cholewa, Andreas Bartenstein, Milan Milošević, Steffen M Berger

Affiliations

  1. Department of Pediatric Surgery, Children's Hospital, Inselspital, University of Bern, Bern, Switzerland.
  2. Department of Biomedical Research, University of Bern, Bern, Switzerland.
  3. Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland.
  4. Department of Human Genetics, University Children's Hospital, Inselspital, Bern, Switzerland.
  5. Department of Pediatric Surgery, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland.
  6. Faculty of Medicine, University of Basel, Basel, Switzerland.
  7. Department of Human Genetics and USA Computation Institute, University of Chicago, Chicago, IL, United States.

PMID: 31544104 PMCID: PMC6729120 DOI: 10.3389/fmed.2019.00187

Abstract

Rhabdoid tumor is a very aggressive and hardly curable pediatric malignancy. It commonly starts in the kidneys but also can occur in the brain, liver, and other organs. The treatment of this tumor usually involves a combination of surgery, radiation, and chemotherapy. Because this tumor is rare, there is still limited experience with a defined standard of care. Cytogenetic analysis is an important routine method to monitor chromosomal aberrations. We have analyzed metaphases of the G-401 rhabdoid tumor cell line. In these cells we have observed metaphases with derivative chromosome 12 arising from partial trisomy 7p. With increasing passage number the numbers of metaphases having this derivative chromosome 12 were found to be higher. In passage number 2 only one metaphase had this pathological chromosome 12. By passage number 10 and passage number 15 about 25 and 95% of this derivative chromosome 12 were found, respectively. We were able to subclone G-401 cells by limiting dilutions and successfully separated cells having apparently normal karyotypes from cells having derivative chromosome 12. Using the cell proliferation assay we showed that clones possessing the derivative chromosome 12 grew more rapidly than clones with normal chromosomes. The cell cycle analysis confirmed this observation. Overall, in this study we describe for the first time a 7p triplication in a rare rhabdoid tumor of kidney. Both types of clones described in this study could be used as a preclinical model to study the involvement of partial chromosome 7 alterations in the development of rhabdoid tumors.

Keywords: FISH assay; G-401 cell line; chromosomal aberration; partial 7p trisomy; pathophysiology; proliferation; rhabdoid tumor

References

  1. Am J Surg Pathol. 1999 Mar;23(3):249-56 - PubMed
  2. Int J Cancer. 1999 Aug 27;82(5):678-86 - PubMed
  3. Semin Oncol. 2001 Oct;28(5 Suppl 17):27-33 - PubMed
  4. Nat Genet. 2003 Aug;34(4):369-76 - PubMed
  5. Cancer Genet Cytogenet. 2004 May;151(1):78-81 - PubMed
  6. J Clin Oncol. 2005 Oct 10;23(29):7312-21 - PubMed
  7. Cancer Lett. 2005 Nov 8;229(1):13-23 - PubMed
  8. Jpn J Clin Oncol. 2010 May;40(5):377-87 - PubMed
  9. Cell. 2010 May 14;141(4):559-63 - PubMed
  10. Brain Res. 2010 Oct 1;1354:15-22 - PubMed
  11. Stem Cell Rev Rep. 2011 Jun;7(2):471-7 - PubMed
  12. Biochim Biophys Acta. 2012 Aug;1826(1):1-12 - PubMed
  13. Cytotechnology. 2013 Oct;65(5):871-85 - PubMed
  14. Brain Tumor Pathol. 2013 Oct;30(4):203-8 - PubMed
  15. Nucleic Acids Res. 2014 Jan;42(Database issue):D1007-12 - PubMed
  16. Acta Haematol. 2014;132(2):244-6 - PubMed
  17. Biochim Biophys Acta. 1989 Jul 28;989(1):1-10 - PubMed
  18. Crit Rev Oncog. 2015;20(3-4):199-216 - PubMed
  19. Urol Oncol. 2016 Jan;34(1):50-6 - PubMed
  20. Cancer Lett. 2016 May 28;375(1):51-61 - PubMed
  21. PLoS One. 2016 May 23;11(5):e0155561 - PubMed
  22. Tumour Biol. 2016 Sep;37(9):11553-11572 - PubMed
  23. Anticancer Res. 2016 Aug;36(8):3883-7 - PubMed
  24. BMC Cancer. 2017 Nov 10;17(1):745 - PubMed
  25. Methods Mol Biol. 2018;1745:305-314 - PubMed
  26. Methods Mol Biol. 2018;1745:315-335 - PubMed
  27. Expert Opin Ther Targets. 2018 Apr;22(4):365-379 - PubMed
  28. Blood. 2018 Jun 28;131(26):2891-2898 - PubMed
  29. Biochem Soc Trans. 2018 Aug 20;46(4):1003-1012 - PubMed
  30. Genes Chromosomes Cancer. 1994 May;10(1):49-54 - PubMed
  31. Cell Biol Int. 1995 May;19(5):389-98 - PubMed
  32. Am J Pathol. 1993 Feb;142(2):375-80 - PubMed
  33. Pediatr Pathol. 1993 Mar-Apr;13(2):249-65 - PubMed
  34. Med Pediatr Oncol. 1996 Sep;27(3):174-8 - PubMed
  35. Genes Chromosomes Cancer. 1996 Jan;15(1):10-7 - PubMed
  36. Genomics. 1997 Dec 15;46(3):355-63 - PubMed

Publication Types